Search company, investor...
Search

Predict your next investment

Corporate Venture
yjventure.com

See what CB Insights has to offer

Investments

10

Portfolio Exits

1

About Yonjin Venture

Yonjin Venture is the North America and Europe investment arm of Yongjin Group (Yongjin) and the sister firm of Yonghua Capital (Yonghua) both based in China with headquarters in Shanghai. It specializes in early- and mid-stage life science companies. It is interested in technologies in therapeutics, diagnostics and medical devices.

Yonjin Venture Headquarters Location

125 Cambridge Park Drive, Suite 301

Cambridge, Massachusetts, 02140,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Yonjin Venture News

Libra Therapeutics Raises $29M in Series A Funding

Sep 23, 2020

Libra Therapeutics, Inc. , a San Diego, CA-based developer of novel drug candidates focused on restoring the cellular balance lost in neurodegenerative diseases, secured $29m in Series A financing. The round was co-led by Boehringer Ingelheim Venture Fund (BIVF), Epidarex Capital, and Santé, joined by Yonjin Venture, Dolby Family Ventures, and Sixty Degree Capital. The financing proceeds will be used primarily to build the team and advance a pipeline of novel small molecule drug candidates for the treatment of neurodegenerative diseases. Led by Isaac Veinbergs, Ph.D., President and CEO, Libra Therapeutics was founded on breakthrough science generated by Axxam S.p.A., a discovery research organization, which provides Libra Therapeutics novel and proprietary chemical matter, cutting edge and exclusive assays, and robust drug discovery expertise. The company’s therapeutic platform is positioned to discover and develop novel small molecule drugs that can both increase autophagy to more rapidly clear toxic proteins and attenuate the production of neurotoxic proteins. FinSMEs 23/09/2020

Yonjin Venture Investments

10 Investments

Yonjin Venture has made 10 investments. Their latest investment was in Bluejay Therapeutics as part of their Series B on August 8, 2022.

CBI Logo

Yonjin Venture Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/16/2022

Series B

Bluejay Therapeutics

$41M

Yes

3

2/9/2022

Series B

Regenacy Pharmaceuticals

$9.3M

No

2

3/31/2021

Series C

OncoResponse

$40.6M

Yes

4

1/1/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

9/23/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/16/2022

2/9/2022

3/31/2021

1/1/2021

9/23/2020

Round

Series B

Series B

Series C

Series C

Series A

Company

Bluejay Therapeutics

Regenacy Pharmaceuticals

OncoResponse

Subscribe to see more

Subscribe to see more

Amount

$41M

$9.3M

$40.6M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

2

4

10

10

Yonjin Venture Portfolio Exits

1 Portfolio Exit

Yonjin Venture has 1 portfolio exit. Their latest portfolio exit was C4 Therapeutics on October 02, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/2/2020

IPO

$99M

Public

2

Date

10/2/2020

Exit

IPO

Companies

Valuation

$99M

Acquirer

Public

Sources

2

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.